levosulpiride / Generic mfg. - LARVOL DELTA

Movement Disorders Associated with Levosulpiride: A Systematic Review of Prevalence, Risk Factors, and Therapeutic Approaches. (PubMed, Neurol India) - "PROSPERO: CRD42024553156."

Journal • Movement Disorders

Drug repurposing: Identification and X-ray crystallographic analyses of US-FDA approved drugs against carbonic anhydrase-II. (PubMed, Int J Biol Macromol) - "From in vivo studies, we found that carbonic anhydrase activity was significantly inhibited by the intraperitoneal administration of levosulpiride for up to 5 h. Our findings provide comprehensive insights for the optimization of the pharmacological profile of these drugs, and provide avenues for the exploration of different derivatives of these drugs with enhanced efficacy and fewer adverse effects."

FDA event • Journal • Glaucoma • Ophthalmology

Updated document on the management of functional dyspepsia by the Asociación Española de Neurogastroenterologia y Motilidad (ASENEM) and Sociedad Española de Medicina Familiar y Comunitaria (semFYC). (PubMed, Rev Esp Enferm Dig) - "Second-line therapy includes neuromodulating agents, among which tricyclic antidepressants and atypical antipsychotics such as levosulpiride stand out...Other therapy alternatives include phytotherapy using STW5 or peppermint/caraway oil, which have shown their superiority over placebo in controlled studies. Concurrently, dietary and lifestyle counseling, as well as psychological interventions such as cognitive-behavioral therapy, when available, may represent a therapeutic alternative worth considering for some patients."

Journal • CNS Disorders • Dyspepsia • Gastroenterology • Infectious Disease • Pain

Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Carmen Clapp | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders • PRL

Nanostructured lipid carriers as a strategy to enhance oral levosulpiride delivery: An in vitro and ex vivo assessment. (PubMed, Int J Pharm) - "The reversible effect on integrity was associated with altered cell morphology confirmed by occludin and f-actin localization with insignificant effect on metabolic activity. These results suggest that the NLCs and/or components thereof can mediate improved absorption of drugs by increasing the permeability of the intestinal epithelial membrane, further facilitated by increased drug solubilization."

Journal • Preclinical • CNS Disorders

Exploring the potential of a pH-sensitive hydrogel sponge: interpenetrating network of tragacanth and pectin for controlled delivery of levosulpiride. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Drug release kinetics was observed to be in zero order. The findings of this study highlight the promising potential of the tragacanth/pectin hydrogel sponge as a pH-sensitive dais for the controlled delivery of levosulpiride, emphasizing its potential application in personalized drug therapy and the treatment of gastrointestinal disorders."

Journal • Gastroenterology • Gastrointestinal Disorder

Prevalence and comparative analysis of potential drug-drug interactions among hospitalized patients at a tertiary care cardiac institute in Pakistan: Findings from a single centre. (PubMed, Pak J Pharm Sci) - "Class C interactions were the most frequent (62.1%), followed by Classes B, D and X. Additionally, the study identified unique pDDIs from Lexicomp, including Ipratropium-Orphenadrine and Furosemide-Levosulpiride, not listed in Micromedex. The findings highlight the high prevalence of pDDIs in this population, emphasizing the need for regular monitoring. Using pDDI screening tools, clinical pharmacists can be crucial in mitigating these risks, particularly in high-risk patients."

Clinical • Journal • Observational data • Cardiovascular

In silico studies, synthesis, characterization and in vitro studies of levosulpiride derivatives. (PubMed, Future Med Chem) - "Most of the derivatives showed strong pharmacokinetic profiles while no drug crossed blood-brain barrier. The newly synthesized L1 and L3 levosulpiride-derived compounds have demonstrated promising anticancer properties against breast cancer cells."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor

Gastroparesis associated to isoniazid. First description. (PubMed, Rev Med Chil) - "Gastroparesis improved with discontinuation of isoniazid and levosulpiride, reappeared with re-exposure, and improved with definitive withdrawal of isoniazid...Gastroparesis associated with isoniazid should be added to the list of adverse effects associated with this drug, even in patients receiving pyridoxine supplementation. Its recognition is initially clinical, can be confirmed with nuclear medicine studies, and affects the eradication of Mycobacterium tuberculosis."

Journal • Gastrointestinal Disorder • Hepatology • Infectious Disease • Inflammation • Pain • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Development and validation of a reversed-phase HPLC-UV method for simultaneous determination of levosulpiride and omeprazole in human plasma: Applicability of the method for evaluation of pharmacokinetic drug-drug interactions. (PubMed, PLoS One) - "In the presented study, a reversed-phase HPLC-UV method was developed for the simultaneous determination of levosulpiride and omeprazole using pantoprazole as the internal standard. Both the changes were insignificant. Similarly, no significant change in the pharmacokinetic parameters of omeprazole was observed with co-administration of levosulpiride."

Journal • PK/PD data • CNS Disorders • Depression • Gastroenterology • Gastrointestinal Disorder • Mood Disorders • Psychiatry

Tritium decay catastrophe. (PubMed, Appl Radiat Isot) - "The phenomenon of tritium decay catastrophe is introduced. A technical example is provided regarding the radioligand [methoxy-3H] levosulpiride whose long-term behavior is consistent with the concept of tritium decay catastrophe."

Journal

Stimuli-responsive glucuronoxylan polysaccharide from quince seeds for biomedical, food packaging, and environmental applications. (PubMed, Int J Biol Macromol) - "In tablet formulations, modified and unmodified QSM as a binder sustained the release of various drugs such as cefixime, capecitabine, diclofenac sodium, theophylline, levosulpiride, diphenhydramine, metoprolol tartrate, and acyclovir sodium. The present review discussed the extraction optimization, chemical composition, stimuli-responsiveness, and viscoelastic properties of mucilage. The potential of mucilage in edible films, tissue engineering, and water purification will also be discussed."

Journal • Review

Efficacy of Pistacia lentiscus Plant (Rumi Mastagi) in Comparison to Levosulpiride in Patients with Diabetic Gastroparesis: A Double-Blind Non-Inferior Randomised Control Trial Study. (PubMed, Indian J Endocrinol Metab) - "To our knowledge, this is the first study to compare the effect of levosulpiride with mastic gum concerning improvement in diabetic gastroparesis (DG) using GES. In the study, mastic gum was found to have great properties to improve DG with many important pleiotropic effects."

Journal • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Solid Tumor

Dopaminergic Drugs and Valproate-associated Refractory Hyponatremia Over Levosulpiride-induced Parkinsonism in an Elderly Female Patient When Deprescribing was the Only Therapy. (PubMed, Curr Drug Saf) - "The case highlights the need to be vigilant for adverse consequences of the prescribing cascade, especially for antiemetic drugs, such as levosulpiride, because of its propensity to induce extrapyramidal reactions in older patients. In cases of refractory hyponatremia, a trial of de-challenge of valproate and dopaminergic drugs should be considered. In addition, the identification and removal of the culprit drugs can rescue the patient from a disabling cycle of adverse drug reactions."

Journal • Cardiovascular • CNS Disorders • Heart Failure • Movement Disorders • Parkinson's Disease • Psychiatry

Fixed drug combination (levosulpiride and rabeprazole)-induced atypical Parkinsonian's disorders with associated anxiety and low-lying depression. (PubMed, Indian J Pharmacol) - "We hereby describe a rare case of levosulpiride-induced atypical parkinsonism presenting with sluggish movements, atypical kinetic tremors (tremors with voluntary movement), periorbital tremors, dystonia, difficulty in speech and coordination, postural imbalance, with additional features of difficulty in swallowing and drooling with associated recent onset psychiatric disturbances such as anxiety and low-lying depression. The dechallenge of levosulpiride and medications for associated anxiety and low-lying depression caused a complete remission of the disease within 2 ½ months."

Journal • CNS Disorders • Depression • Dystonia • Mental Retardation • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Real-world safety and effectiveness of Pistacia lentiscus (mastic gum) in patients with diabetic gastroparesis: 24-week interim analysis postintervention. (PubMed, Indian J Pharmacol) - "Six-month (24-week) interim analysis of patients suggests that mastic gum gives a sustainable improvement in DG symptoms without any obvious adverse effects as compared to levosulpiride."

Journal • Real-world • Real-world evidence • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Solid Tumor

Efficacy of prokinetic agents in diabetic gastroparesis comparing symptomatology and scintigraphy - An open-label trial. (PubMed, Caspian J Intern Med) - "Levosulpiride was significantly more effective than Cinitapride in improving individual symptoms like nausea, vomiting, stomach fullness, and early satiety. Levosulpiride is better than Cinitapride in improving the symptoms of diabetic gastroparesis but no significant effect on gastric scintigraphy."

Journal • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

Prevalence and Choice of Pharmacologic Management of Functional Dyspepsia and Irritable Bowel Syndrome During Pregnancy (ACG 2023) - "Pylori Antibiotics = Metronidazole, Clarithromycin, Levofloxacin, Tetracycline, Doxycycline, Tinidazole, Nitazoxanide, Rifabutin. Anti-Diarrheals = Loperamide, Diphenoxylate, Bismuth Salicylate. Bile Acid Sequestrants = Cholestyramine, Colesevelam, Colestipol. Bowel Stimulants = Bisacodyl, Sennosides. Exposure to IBS or FD medications was significantly elevated in IBSFD compared to NONE. 17,984 of 48,208 IBSFD patients (37%) were exposed to proton pump inhibitors compared to 266,835 of 3,046,065 (9%) of NONE (OR 6.20; 95% CI 6.08 - 6.52). 1.4% of IBSFD were exposed to Rifaximin compared to 0.032% of NONE (OR 44.44; CI 40.19 - 49.14)."

Dyspepsia • Gastrointestinal Disorder

Lansoprazole plus levosulpiride versus esomeprazole in participants with gastroesophageal reflux disease and erosive esophagitis: a double blinded randomized control trial. (PubMed, Ann Med Surg (Lond)) - "Although quality of life worsened in both groups, adverse effects did not significantly differ. These findings strongly support the use of lansoprazole plus levosulpiride as a preferred treatment option for GERD and erosive esophagitis, which could have significant clinical implications for managing this common condition."

Journal • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Enhanced Antidepressant Activity of Nanostructured Lipid Carriers Containing Levosulpiride in Behavioral Despair Tests in Mice. (PubMed, Pharmaceuticals (Basel)) - "An acute toxicity study revealed no significant changes in organ-to-body weight ratio, serum biochemistry or tissue histology of major organs. It can be concluded that nanostructured lipid carriers can efficiently deliver LSP to the brain for improved therapeutic efficacy."

Journal • Preclinical • CNS Disorders • Depression • Psychiatry

Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial. (PubMed, Eye (Lond)) - "Oral levosulpiride for 8 weeks improved visual and structural outcomes in patients with centre-involving DME by mechanisms that may include intraocular upregulation of vasoinhibin and downregulation of VEGF and PlGF. Larger clinical trials evaluating long-term efficacy and safety are warranted."

Clinical • Journal • P2 data • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

A comparison of different symptomatic reflux esophagitis treatments: A real-world study. (PubMed, Adv Clin Exp Med) - "The study consisted of 6 sequentially administered medical treatments for GERD, lasting 2 months, with a 3-week washout period between each drug schedule: Group A: PPI (esomeprazole 40 mg/day before breakfast); Group B: mucosal protective drugs (a combination of hyaluronic acid, chondroitin sulfate and poloxamer 407, or a combination of hyaluronic acid, chondroitin sulfate and aluminum, 3 times daily after a meal); Group C: prokinetics (levosulpiride 25 mg or domperidone 10 mg, 3 times daily before a meal); Group D: barrier drug (alginate 3 times daily after a meal); Group E: PPI (esomeprazole 40 mg/day before breakfast) and mucosal protective drugs (a combination of hyaluronic acid, chondroitin sulfate and poloxamer 407, or a combination of hyaluronic acid, chondroitin sulfate and aluminum, before sleep); Group F: PPI (esomeprazole 40 mg/day before breakfast) and prokinetics (levosulpiride 25 mg or domperidone 10 mg before lunch and dinner). Using PPIs and mucosal..."

Journal • Real-world • Real-world evidence • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Pain

Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Carmen Clapp | Trial completion date: Feb 2024 ➔ Jun 2025 | Trial primary completion date: Nov 2023 ➔ Jun 2025

Trial completion date • Trial primary completion date • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders • Solid Tumor • PRL

Regulation of plasma glucose levels by central dopamine D receptors is impaired in type 1 but not type 2 diabetic mouse models. (PubMed, Eur J Pharmacol) - "Intracerebroventricular injections of both the dopamine D receptor agonist quinpirole and the antagonist l-sulpiride induced hyperglycemia in control mice, but not in streptozotocin (STZ)-induced diabetic mice, a type 1 diabetic model. These results indicate that (i) stimulation or blockade of dopamine D receptors causes hyperglycemia by increasing hepatic glycogenolysis, and (ii) stimulation or blockade of dopamine D receptors does not affect glucose levels in type 1 but does so in type 2 diabetic models. Moreover, hypothalamic dopaminergic function and hepatic glycogenolysis are decreased in the type 1 diabetic model, which reduces hyperglycemia induced by stimulation or blockade of dopamine D receptors."

Journal • Preclinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Levosulpiride-Induced Hyperprolactinemia for the Treatment of Diabetic Macular Edema: A Phase 2 Pilot Clinical Trial (ENDO 2023) - "In conclusion, oral levosulpiride administration for 8 weeks improved visual and structural outcomes in patients with center involving DME by mechanisms that may include intraocular upregulation of vasoinhibin and downregulation of VEGF and PlGF. Larger clinical trials evaluating long-term efficacy and safety are warranted."

Clinical • P2 data • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • DRD2